Fizyhealth
BoomRx company profile

BoomRx company profile: what is public, what is not

BoomRx is a Tampa-based national pharmaceutical technology platform that unifies access to 503A, 503B, and brand medications through one ordering portal at boomrx.com. Publicly verifiable facts include a July 2025 launch, leadership names from company press releases, and March 2026 metrics reporting 1,750+ clinics and more than $15.5 million in net order revenue — but BoomRx does not publish a full partner pharmacy list, HIPAA documentation, or contract terms on its public site as of June 2026.

If you are doing vendor due diligence on BoomRx as a company, this page separates the publicly verifiable facts from the details BoomRx does not disclose — without filling the gaps with guesses.

Compare Fizy Health vs BoomRx

Proudly Partnered With

What is publicly verifiable about BoomRx?

What can be verified from BoomRx's public materials is the product, its leadership, and recent scale metrics. BoomRx is a business-to-business pharmaceutical technology platform, reachable at boomrx.com, that lets clinics order compounded and manufactured medications across 503A compounders, FDA-registered 503B outsourcing facilities, and brand sources from one dashboard with competitive pricing and a $30 flat-rate cold-chain shipping fee. A March 4, 2026 press release on boomrx.com/resources reports the platform launched in July 2025, surpassed $15.5 million in net order revenue, serves more than 1,750 clinics nationwide, and averages more than 8,000 orders per month with more than 85% of clinics returning to reorder. Kurt Lunkwitz is identified as founder and president; Fabian Calvo is identified as co-founder in a media appearance listed on the resources page. What is not on the public site, as of June 2026, is a named list of partner pharmacies, published HIPAA or BAA documentation, detailed contract terms, or a public support phone number.

Who needs this profile

Due diligence falls to the people signing the contract.

A company profile matters most to the roles responsible for vendor risk before a clinic commits. Three of them carry that weight.

  • Owners

    Founders accepting vendor risk.

    Owners sign the agreement, so they carry the risk of a fast-scaling vendor whose partner list is not public. Their question is what can be confirmed about the company's stability — launch date, disclosed clinic count, repeat utilization — and what they should request directly about contracting entity and pharmacy partners.

  • Operators

    Ops leads assessing reliability.

    Operations staff depend on the platform daily, so company longevity and support responsiveness matter to them. With only form-based onboarding and assigned customer care agents publicly documented, they evaluate reliability through references, contract terms, and onboarding responsiveness rather than a published support SLA.

  • Prescribers

    Providers confirming legitimacy.

    Prescribers want assurance the platform routes to legitimate, licensed 503A and 503B pharmacies. Since BoomRx does not publish a partner list, their due diligence centers on verifying the certification and licensure of the pharmacies behind each order during onboarding.

What BoomRx does not publish

As of June 2026, BoomRx's public site does not disclose the specific 503A and 503B partner pharmacies it routes to, published HIPAA or business associate agreement documentation, detailed refund and cancellation policy terms, or a public support phone number. It also does not name outside investors or funding amounts on boomrx.com, though a March 2026 press release does report revenue and order-volume milestones. Where a fact is not in BoomRx's public materials, it is undisclosed rather than estimated here.

The relationship between boomrx.com and boomrxconnect.com — which carries a WellSync copyright notice — is not fully explained on the main site. Treat boomrxconnect.com as a related access point and confirm which domain your clinic will use during onboarding. This is common for fast-growing B2B platforms and is not, by itself, a red flag — but it does mean due diligence has to come from direct requests.

What to ask BoomRx directly

Because several corporate and compliance facts are not public, request them in the onboarding conversation: ask which legal entity you are contracting with, who stands behind the platform, and how boomrx.com relates to boomrxconnect.com. Ask for the specific 503A and 503B partner pharmacies your clinic would route to and proof of their state licensure and any third-party certification, since the platform's legitimacy ultimately rests on its partners. Ask for references from clinics like yours, confirm how the $30 flat-rate shipping fee applies, and read the contract and cancellation terms before signing.

On the parts you can verify yourself, confirm the platform is a B2B clinic procurement tool at boomrx.com with 503A, 503B, and brand access, competitive pricing confirmed after signup, and automated patient SMS delivery updates. For a transparent point of comparison, Fizy Health publishes its model openly — pass-through per-vial 503A pricing before checkout, a disclosed facilitation fee, LegitScript-certified partners, and a BAA at onboarding — which is the kind of visibility to look for when a vendor's compliance documentation is thin on the public site.

After due diligence — which platform fits your clinic?

BoomRx fits if

BoomRx

You want one procurement portal across 503A, 503B, and brand meds.

  • You are satisfied with what BoomRx confirms directly about its company, partners, and March 2026 scale metrics.
  • A $30 flat-rate cold-chain shipping fee and EMR integrations matter more than pass-through pricing visible before you quote.
  • You need 503B and brand-med breadth in the same hub as 503A compounded products.
Consider Fizy Health if

Fizy Health

You want every patient line in one HIPAA-audited cart with pass-through pricing.

  • You want a vendor that publishes its pricing model and LegitScript-certified partner approach openly.
  • You want SIG and licensure issues caught before payment — not after the pharmacy rejects the order.
  • You batch refills across multiple 503A partners and want one cart, one validation pass, one checkout.
If you choose Fizy Health

What your clinic gets from a transparent patient-linked platform.

BoomRx and Fizy Health both consolidate 503A ordering. These are the outcomes that show up when pricing and the partner model are visible before you commit.

See all features
Keep evaluating BoomRx

More answers in the BoomRx evaluation guide.

See the full BoomRx guide
FAQ

Company questions clinics ask about BoomRx.

  • Company

    What is BoomRx as a company?

    BoomRx is a Tampa-based national pharmaceutical technology platform at boomrx.com that connects clinics to 503A, 503B, and brand medication partners. It launched in July 2025 and reported more than 1,750 clinics and $15.5 million in net order revenue in a March 2026 press release.

  • Leadership

    Who leads BoomRx?

    A March 2026 BoomRx press release identifies Kurt Lunkwitz as founder and president. Fabian Calvo is identified as co-founder in a media appearance listed on boomrx.com/resources. Ask which legal entity you are contracting with during onboarding.

  • Scale

    How many clinics use BoomRx?

    A March 4, 2026 press release on boomrx.com/resources reports the portal is utilized by more than 1,750 clinics nationwide, averaging more than 8,000 orders per month, with more than 85% of clinics returning to reorder. Ask directly for references from clinics like yours.

  • Funding

    Has BoomRx raised funding?

    BoomRx does not disclose funding history or outside investors on its public site as of June 2026. The March 2026 press release reports revenue and order-volume milestones but not investment amounts, so funding details are undisclosed rather than guessed here.

  • Diligence

    What should I verify before signing with BoomRx?

    Confirm the contracting entity, the specific 503A and 503B partner pharmacies and their state licensure, HIPAA and BAA terms, references from comparable clinics, how the $30 shipping fee applies, and the contract and cancellation terms. The platform's legitimacy rests on its licensed partners.

  • Alternative

    How transparent is Fizy Health by comparison?

    Fizy Health publishes its model openly: pass-through per-vial 503A pricing shown before checkout, a disclosed facilitation fee, LegitScript-certified partners, and a BAA at onboarding — the kind of visibility to look for when a vendor's compliance documentation is not on the public site.

Sources reviewed June 2026

  • BoomRx public website (boomrx.com), reviewed June 2026.
  • BoomRx press releases on boomrx.com/resources, reviewed June 2026.
  • BoomRx Connect (boomrxconnect.com), reviewed June 2026.
  • Fizy Health platform capabilities reflect the live product.
Evaluate with real numbers

Choose a platform that shows its model up front.

See how Fizy Health shows landed cost before you quote, validates orders before you pay, and keeps every line tied to a patient. Free to start.

Fizy Health vs BoomRxStart Ordering Free